title: Lipid management in chronic kidney disease, hemodialysis, and transplantation.
abstract: Recent studies have shown the spectrum of dyslipidemia in patients who have chronic kidney disease (CKD) or end-stage renal disease to be different from that of the general population. This article discusses the pathophysiology of dyslipidemia in CKD, dialysis, and renal transplant patients, the therapeutic options, and their association with clinical outcomes. Whenever possible, comparisons are made to outcomes in the general population.
authors.affiliation: Division of Kidney Disease and Hypertension, 593 Eddy Street, APC 9, Brown Medical School, Providence, RI 02903, USA. tmontague@lifespan.org
authors.forename: Terri
authors.initials: T
authors.lastname: Montague
authors.forename: Barbara
authors.initials: B
authors.lastname: Murphy
mesh_terms: D002318:Cardiovascular Diseases / Q000401:mortality; D002908:Chronic Disease; D050171:Dyslipidemias / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D017408:Guidelines as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000150:complications* / Q000453:epidemiology / Q000601:surgery / Q000628:therapy; D016030:Kidney Transplantation / Q000502:physiology*; D006435:Renal Dialysis
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents